Your privacy, your choice

We use essential cookies to make sure the site can function. We also use optional cookies for advertising, personalisation of content, usage analysis, and social media.

By accepting optional cookies, you consent to the processing of your personal data - including transfers to third parties. Some third parties are outside of the European Economic Area, with varying standards of data protection.

See our privacy policy for more information on the use of your personal data.

for further information and to change your choices.

You are viewing the site in preview mode

Skip to main content

Table 1 A number of Jakinibs and STAT inhibitors

From: The role of JAK-STAT signaling pathway and its regulators in the fate of T helper cells

Drug

Targt

Disease

Status

Ruxolitinib (INC424)

JAK1, JAK2

Polycythemia, Psoriasis (topical), myelofibrosis, Various cancers,

FDA approved

Tofacitinib

JAK3 > JAK1> > (JAK2)

RA, Psoriasis, Spondyloarthropathy, Transplant rejection, ulcerative colitis

FDA approved

Oclacitinib

JAK1

Canine allergic dermatitis

FDA approved

Baricitinib

JAK1, JAK2

RA Psoriasis, diabetic nephropathy, SLE, Atopic dermatitis

Phase III Phase II

Momelitinib

JAK1, JAK2

Myelofibrosis

Phase III

Peficitinib

JAK1, JAK3

RA Psoriasis

Phase III Phase II

INCB039110

JAK1, JAK2

Psoriasis, RA

Phase II

AZD1480

JAK1, JAK2

Myeloproliferative diseases, various cancers

Phase I

ISIS-STAT3Rx (AZD9150)

STAT3

Various cancers

Phase II

OPB-31121

STAT3

Various cancers

Phase I

Back to article page

Cell Communication and Signaling

ISSN: 1478-811X